Drug intelligence / Profile preview

Z009

Development stage: Preclinical
Lead developer: Ziphius Vaccines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

Z009 is a self-amplifying RNA (saRNA) vaccine candidate developed by Ziphius for the prevention of *Chlamydia trachomatis* infection. The vaccine leverages Ziphius's proprietary saRNA technology, which incorporates an alphavirus-derived replicase to enable the intracellular replication of the RNA template. This mechanism allows for sustained expression of the encoded *Chlamydia trachomatis* antigens, aiming to induce a robust and durable immune response while requiring a lower dose compared to traditional mRNA vaccines. Z009 is currently in the preclinical stage of development.

Other names: Z009-Ziphius-self-amplifying RNA (saRNA)-Chlamydia trachomatis

Targets

Chlamydia trachomatis

Beyond the preview

Go deeper on Z009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z009.

Explore the full profile